Physician profile
Myron J Levin
NPI 1306920038
$291,776.79
in general payments reported to CMS, 2019-2025
19 companies · $47K in 2025
The $47K reported for 2025 was more than what 94% of Pediatric Infectious Diseases providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $39K · 2021: $40K · 2022: $51K · 2023: $53K · 2024: $29K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $112K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $3,216 · Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $112,470.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,637.30 |
| Travel and Lodging | $3,216.15 |
| Food and Beverage | $1,298.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $59,554.91 | 2019-2025 | Bexsero |
| Pfizer INC. | $49,342.72 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $31,431.75 | 2021-2025 | Flumist Quadrivalent |
| Seqirus USA INC | $30,235.72 | 2021-2024 | Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $22,941.29 | 2019-2021 | |
| Astrazeneca Uk Limited | $18,522.32 | 2022 | |
| Modernatx, INC. | $16,713.57 | 2022-2025 | |
| Dynavax Technologies Corporation | $15,075.00 | 2021-2025 | Heplisav-B |
| Sanofi Pasteur INC. | $13,165.25 | 2024-2025 | |
| Pfizer International LLC | $9,960.73 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,287.50 | 2020 | |
| Sobi, INC | $5,218.40 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,140.00 | 2021-2023 | |
| Bavarian Nordic A/S | $3,250.00 | 2020 | |
| Genentech, INC. | $2,812.50 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,500.00 | 2022 | |
| Saol Therapeutics INC. | $1,625.13 | 2019-2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myron Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.